Jason Wright

Dr. Wright joined Apexigen in October 2019 as Vice President, CMC. Before joining Apexigen, he served as Vice President of Manufacturing at Proclara Biosciences, where he established and oversaw all CMC activities. Prior to Proclara, Dr. Wright served as Head of CMC for Cambridge Antibody Technology (a subsidiary of AstraZeneca), leading multidisciplinary teams for CAT’s oncology projects, including LUMOXITI®. At Rinat Neuroscience, he was the CMC project lead for multiple programs (including tanezumab and ponezumab) prior to the acquisition by Pfizer and established and managed the internal Cell Culture and Fermentation group. Earlier in his career, Dr. Wright worked in R & D groups at Bayer and Boehringer Mannheim in Germany.

Dr. Wright is an Industry veteran with almost 20 years of experience managing CMC programs for biologics. Dr. Wright received his Doctorate in Cellular Biotechnology from the Swiss Federal Institute of Technology Lausanne (EPFL). He also holds a Masters in Biomedical Sciences from the University of Glasgow and a BSc in Process Biotechnology from the University of Teesside in the UK.